Investors
Analyst Report Evaluates the Development of Canify AG Extremely Positively
According to the latest report from international industry experts Zuanic & Associates, Canify AG is expected to increase its revenue by six times by 2027, compared to 2024. By the end of 2025, a revenue of 21 million euros is anticipated. Key factors contributing to this growth include unique selling points such as diversified supply chains, an in-house EU-GMP processing facility, and a steadily growing portfolio of innovative pharmaceutical products.
Canify Hauptversammlung 2024 (General Assembly)
Canify Hauptversammlung 2023 (General Assembly)
Canify Convertible Bond 2024/2026
Canify Convertible Bond 2023/2026
Convertible Bond 2023/24
Wertpapier-Informationsblatt (Securities Information Sheet) - Share placement completed!
Investors
Good reasons for an investment
Billions are already being generated with medical cannabis. Nevertheless, the European market is still in its early stages. Industry revenue is expected to grow from USD 2.6 billion in 2024 to USD 12.6 billion by 2033 (source: imarcgroup.com).
The Canify management team brings together expertise from the fields of pharmaceuticals, cannabis, finance, and capital markets. Together, the team has more than 100 years of experience in the healthcare sector.
As a GMP-certified pharmaceutical company, we deliver the highest quality, have built a scalable platform, and develop innovative products.
Since the second half of 2024, Canify AG has been profitable. We are now aiming for strong continued growth and scaling, laying the groundwork for an IPO at a significantly higher valuation.
Analyst report rates the development of Canify AG as extremely positive.
Watch industry analyst Pablo Zuanic in conversation with the executive board of Canify AG:
By loading the video, you agree to YouTube's privacy policy.
Learn more
We’d be happy to keep you informed.
Feel free to sign up to be added to our investor mailing list.